Longeveron (LGVN) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
15 Jul, 2026Opening remarks and agenda
The meeting was called to order by the Executive Chairman, welcoming attendees to the fifth annual virtual meeting and outlining procedures for stockholder participation and questions.
Executive officers and independent auditors were introduced, with auditors available for questions.
Procedural matters included proof of notice, availability of proxy materials, and confirmation of quorum.
Board and executive committee updates
Three Class II directors were nominated for election to serve three-year terms expiring at the 2029 annual meeting.
No additional nominations were received before the deadline.
Shareholder proposals
Proposals included electing directors, increasing authorized Class A shares to 175 million, approving a reverse stock split (1:2 to 1:20), amending the 2021 Incentive Award Plan to add 5 million shares, ratifying the appointment of CBIZ as auditors, and authorizing adjournment if needed for further proxy solicitation.
Latest events from Longeveron
- Directors elected, incentive plan amended, and auditors ratified at the annual meeting.LGVN
AGM 20248 Jul 2026 - Revenue up 177% and pivotal trials advanced, but more funding may be needed for late-stage work.LGVN
Q3 20248 Jul 2026 - Key proposals include director elections, share increases, and a reverse stock split to maintain listing.LGVN
Proxy filing20 May 2026 - Virtual meeting to vote on directors, capital changes, and auditor, with online proxy access.LGVN
Proxy filing20 May 2026 - Net loss narrowed to $4.7M in Q1 2026, but future operations require new funding and partnerships.LGVN
Q1 202619 May 2026 - Capital-light strategy and licensing focus position laromestrocel for major value inflection in 2026.LGVN
Investor presentation13 May 2026 - Annual meeting covers director elections, share structure changes, incentive plan, and auditor ratification.LGVN
Proxy filing5 May 2026 - HLHS Phase 2b data and PRV eligibility position laromestrocel for major value inflection.LGVN
Investor presentation4 May 2026 - Biotech registers resale of shares amid financial uncertainty and ongoing clinical development.LGVN
Registration filing10 Apr 2026